公开(公告)号：US11998544B2

公开(公告)日：2024-06-04

申请号：US17059876

申请日：2019-05-31

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Ermira Pazolli ,  Silvia Buonamici ,  James Palacino ,  Michael Seiler ,  Ping Zhu ,  Evan Barry ,  Lihua Yu

IPC: A61K31/496 ,  A61K35/17 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K39/00 ,  A61K39/39 ,  A61K39/395 ,  A61K47/68

CPC classification number: A61K31/496 ,  A61K35/17 ,  A61K38/191 ,  A61K38/2013 ,  A61K38/2066 ,  A61K38/208 ,  A61K38/2086 ,  A61K38/217 ,  A61K39/0011 ,  A61K39/39 ,  A61K39/3955 ,  A61K47/6803 ,  A61K2039/6031 ,  A61K2039/6037 ,  A61K2039/6056 ,  A61K2039/6081

Abstract: This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.

公开(公告)号：US11352348B2

公开(公告)日：2022-06-07

申请号：US17247117

申请日：2020-11-30

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Ermira Pazolli ,  Silvia Buonamici ,  Thiwanka Samarakoon ,  Sudeep Prajapati ,  Nathan Fishkin ,  James Palacino ,  Michael Seiler ,  Ping Zhu ,  Andrew Cook ,  Peter Smith ,  Xiang Liu ,  Shelby Ellery ,  Dominic Reynolds ,  Lihua Yu ,  Zhenhua Wu ,  Shouyong Peng ,  Nicholas Calandra ,  Megan Sheehan ,  Yonghong Xiao

IPC: C07D405/12 ,  A61P35/00 ,  A61K47/68 ,  A61K47/60 ,  A61K9/127 ,  A61K9/51 ,  A61K31/365 ,  A61K31/496 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  C07D313/00 ,  C07D405/06 ,  C07K16/24 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K16/40 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/574

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

公开(公告)号：US12172986B2

公开(公告)日：2024-12-24

申请号：US17059635

申请日：2019-05-31

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Ermira Pazolli ,  Silvia Buonamici ,  Thiwanka Samarakoon ,  Sudeep Prajapati ,  Nathan Fishkin ,  James Palacino ,  Michael Seiler ,  Ping Zhu ,  Andrew Cook ,  Peter Smith ,  Xiang Liu ,  Shelby Ellery ,  Dominic Reynolds ,  Lihua Yu ,  Zhenhua Wu ,  Shouyong Peng ,  Nicholas Calandra ,  Megan Sheehan ,  Yonghong Xiao

IPC: C07D405/12 ,  A61K9/127 ,  A61K9/51 ,  A61K31/365 ,  A61K31/496 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/60 ,  A61K47/68 ,  A61P35/00 ,  C07D313/00 ,  C07D405/06 ,  C07K16/24 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K16/40 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/574

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

公开(公告)号：US11945807B2

公开(公告)日：2024-04-02

申请号：US17661909

申请日：2022-05-03

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Ermira Pazolli ,  Silvia Buonamici ,  Thiwanka Samarakoon ,  Sudeep Prajapati ,  Nathan Fishkin ,  James Palacino ,  Michael Seiler ,  Ping Zhu ,  Andrew Cook ,  Peter Smith ,  Xiang Liu ,  Shelby Ellery ,  Dominic Reynolds ,  Lihua Yu ,  Zhenhua Wu ,  Shouyong Peng ,  Nicholas Calandra ,  Megan Sheehan ,  Yonghong Xiao

IPC: C07D405/12 ,  A61K9/127 ,  A61K9/51 ,  A61K31/365 ,  A61K31/496 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/60 ,  A61K47/68 ,  A61P35/00 ,  C07D313/00 ,  C07D405/06 ,  C07K16/24 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K16/40 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/574

CPC classification number: C07D405/12 ,  A61K9/127 ,  A61K9/51 ,  A61K31/365 ,  A61K31/496 ,  A61K39/0011 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/60 ,  A61K47/6845 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6857 ,  A61K47/6869 ,  A61K47/6871 ,  A61K47/6889 ,  A61P35/00 ,  C07D313/00 ,  C07D405/06 ,  C07K16/24 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2896 ,  C07K16/3007 ,  C07K16/3092 ,  C07K16/32 ,  C07K16/40 ,  C12Q1/6886 ,  G01N33/5011 ,  G01N33/574 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/545 ,  C07K2317/565 ,  C07K2317/76 ,  C12Q2600/106 ,  G01N2500/10

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.